Janus kinase inhibitor Abrocitinib as an Off‐Label treatment for tattoo granuloma with uveitis ( TAGU )
Australasian Journal of Dermatology · 2024
DOI: 10.1111/ajd.14248 ↗Kurz gefasst
Leserbrief in der Zeitschrift Australasian Journal of Dermatology, 2024. Verfasst von Yutong Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Photomedicine, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Off-Label Use, Uveitis, Janus Kinase Inhibitors, Tattooing. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 4 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Photomedicine, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, China.
- Department of Dermatopathology, Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.
ORCID-Profile: Yutong Yang, Jia Yan, Jin Yang, Peiru Wang, Yeqiang Liu, Xiuli Wang
Zitieren
APA
Yang, Y., Yan, J., Yang, J., Wang, P., Liu, Y., & Wang, X. (2024). Janus kinase inhibitor Abrocitinib as an Off‐Label treatment for tattoo granuloma with uveitis ( TAGU ). Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.14248
Vancouver
Yang Y, Yan J, Yang J, Wang P, Liu Y, Wang X. Janus kinase inhibitor Abrocitinib as an Off‐Label treatment for tattoo granuloma with uveitis ( TAGU ). Australasian Journal of Dermatology. 2024. doi:10.1111/ajd.14248
BibTeX
@article{Yang2024,
author = {Yang, Yutong and Yan, Jia and Yang, Jin and Wang, Peiru and Liu, Yeqiang and Wang, Xiuli},
title = {Janus kinase inhibitor Abrocitinib as an Off‐Label treatment for tattoo granuloma with uveitis ( TAGU )},
journal = {Australasian Journal of Dermatology},
year = {2024},
doi = {10.1111/ajd.14248}
}
EUVIMED